Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 12/2018

01-12-2018 | Review

Bone management in hematologic stem cell transplant recipients

Authors: D. L. Kendler, J. J. Body, M. L. Brandi, R. Broady, J. Cannata-Andia, M. J. Cannata-Ortiz, A. El Maghraoui, G. Guglielmi, P. Hadji, D. D. Pierroz, T. J. de Villiers, R. Rizzoli, P. R. Ebeling, for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease

Published in: Osteoporosis International | Issue 12/2018

Login to get access

Abstract

Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some malignant and non-malignant hematological diseases. Advances in transplantation techniques and supportive care measures have substantially increased the number of long-term HSCT survivors. This has led to an increasing patient population suffering from the late effects of HSCT, of which, bone loss and its consequent fragility fractures lead to substantial morbidity. Altered bone health, with consequent fragility fractures, and chronic graft-versus-host disease (GVHD) are factors affecting long-term quality of life after HSCT. Hypogonadism, HSCT preparative regimens, nutritional factors, and glucocorticoids all contribute to accelerated bone loss and increased fracture risk. Management strategies should include bone mineral density examination, evaluation of clinical risk factors, and general dietary and physical activity measures. Evidence has accumulated permitting recommendations for more attentiveness to evaluation and monitoring of bone health, with appropriate application of osteoporosis pharmacotherapies to patients at increased risk of bone loss and fracture.
Literature
1.
McClune BL, Majhail NS (2013) Osteoporosis after stem cell transplantation. Curr Osteoporos Rep 11:305–310PubMedCrossRef
2.
Takayanagi H (2015) SnapShot: osteoimmunology. Cell Metab 21(502):e501
3.
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401–419PubMedCrossRef
4.
5.
Ria R, Scarponi AM, Falzetti F et al (2007) Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. Leuk Lymphoma 48:923–930PubMedCrossRef
6.
Lee SJ, Vogelsang G, Flowers ME (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9:215–233PubMedCrossRef
7.
Joseph RW, Alousi A, Konda B et al (2011) High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86:954–956PubMedCrossRef
8.
Hadji P, Ziller M, Maskow C, Albert U, Kalder M (2009) The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 45:3205–3212PubMedCrossRef
9.
Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98–109PubMedCrossRef
10.
Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, Crump M, Derzko C, Keating A (1998) Ovarian function after autologous bone marrow transplantation. J Clin Oncol 16:2359–2363PubMedCrossRef
11.
Serio B, Pezzullo L, Fontana R et al (2013) Accelerated bone mass senescence after hematopoietic stem cell transplantation. Transl Med UniSa 5:7–13PubMedPubMedCentral
12.
Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP (1998) Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 92:3465–3473PubMedCrossRef
13.
Philibert D, Desmeules S, Filion A, Poirier M, Agharazii M (2008) Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant 23:359–363PubMedCrossRef
14.
Weilbaecher KN (2000) Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:165–174CrossRefPubMed
15.
Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP (1999) Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342–350CrossRefPubMed
16.
Schulte C, Beelen DW, Schaefer UW, Mann K (2000) Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11:344–353PubMedCrossRef
17.
Bhatia S (2011) Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 4:437–452 quiz 453–434PubMedPubMedCentralCrossRef
18.
Anandi P, Jain NA, Tian X, Wu CO, Pophali PA, Koklanaris E, Ito S, Savani BN, Barrett J, Battiwalla M (2016) Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors. Bone Marrow Transplant 51:1101–1106PubMedCrossRef
19.
Ebeling PR (2013) Transplantation osteoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 8th Edition:495–507CrossRef
20.
Buchs N, Helg C, Collao C, Chapuis B, Slosman D, Bonjour JP, Rizzoli R (2001) Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Osteoporos Int 12:880–886PubMedCrossRef
21.
Ebeling PR (2005) Bone disease after bone marrow transplantation bone disease of organ transplantation. In: Compston J, Shane E (eds) , vol 19. Elsevier, Academic Press chap, London, pp 339–352CrossRef
22.
Pawlowska M, Yang Q, Hamata B, Kendler DL, Broady R (2016) Early changes in bone mineral density and trabecular bone score following allogeneic stem cell transplant. Bone Marrow Transplant 51:738–740PubMedCrossRef
23.
Lee WY, Baek KH, Rhee EJ, Tae HJ, Oh KW, Kang MI, Lee KW, Kim SW, Kim CC, Oh ES (2004) Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant 34:89–94PubMedCrossRef
24.
Gandhi MK, Lekamwasam S, Inman I et al (2003) Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 121:462–468PubMedCrossRef
25.
Champlin RE (2003) Selection of autologous or allogeneic transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR et al (eds) Holland-Frei cancer medicine, 6th edn. BC Decker, Hamilton (ON)
26.
27.
Pundole XN, Barbo AG, Lin H, Champlin RE, Lu H (2015) Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol 33:1364–1370PubMedPubMedCentralCrossRef
28.
Pundole X, Cheema HI, Petitto GS, Lopez-Olivo MA, Suarez-Almazor ME, Lu H (2017) Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis. Bone Marrow Transplant 52:663–670PubMedCrossRef
29.
Lin JN, Chen HJ, Yang CH, Lai CH, Lin HH, Chang CS, Liang JA (2017) Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study. Oncotarget 8:34811–34819PubMedPubMedCentralCrossRef
30.
Savani BN, Donohue T, Kozanas E, Shenoy A, Singh AK, Childs RW, Barrett AJ (2007) Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 13:517–520PubMedCrossRef
31.
Berenson JR, Lichtenstein A, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma Myeloma Aredia Study Group. N Engl J Med 334:488–493PubMedCrossRef
32.
Raje N, Terpos E, Willenbacher W et al (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19:370–381PubMedCrossRef
33.
34.
Weitzmann MN, Pacifici R (2005) Role of the immune system in postmenopausal bone loss. Curr Osteoporos Rep 3:92–97PubMedCrossRef
35.
Nakashima T, Hayashi M, Takayanagi H (2012) New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 23:582–590PubMedCrossRef
36.
37.
38.
Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255–259PubMedCrossRef
39.
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481–1488PubMedPubMedCentralCrossRef
40.
Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ (2002) TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143:1108–1118PubMedCrossRef
41.
Kobayashi K, Takahashi N, Jimi E et al (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275–286PubMedPubMedCentralCrossRef
42.
Nanes MS (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321:1–15PubMedCrossRef
43.
Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49–60PubMedCrossRef
44.
45.
Takayanagi H, Ogasawara K, Hida S et al (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605PubMedCrossRef
46.
Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117:122–132PubMedCrossRef
47.
Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S, Walker EC, Martin TJ, Gillespie MT (2008) IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 181:5720–5729PubMedCrossRef
48.
Quach JM, Askmyr M, Jovic T, Baker EK, Walsh NC, Harrison SJ, Neeson P, Ritchie D, Ebeling PR, Purton LE (2015) Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J Bone Miner Res 30:886–897PubMedCrossRef
49.
Yao S, Sucheston LE, Smiley SL, Davis W, Conroy JM, Nowak NJ, Ambrosone CB, McCarthy PL Jr, Hahn T (2011) Common genetic variants are associated with accelerated bone mineral density loss after hematopoietic cell transplantation. PLoS One 6:e25940PubMedPubMedCentralCrossRef
50.
Gao L, Zhang Y, Hu B et al (2016) Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol 34:2843–2850PubMedCrossRef
51.
Sui B, Hu C, Zhang X, Zhao P, He T, Zhou C, Qiu X, Chen N, Zhao X, Jin Y (2016) Allogeneic mesenchymal stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid-induced osteoporosis. Stem Cells Transl Med 5:1238–1246PubMedPubMedCentralCrossRef
52.
Phetfong J, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasittikul V, Supokawej A (2016) Osteoporosis: the current status of mesenchymal stem cell-based therapy. Cell Mol Biol Lett 21:12PubMedPubMedCentralCrossRef
53.
Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ (2001) Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 7:257–264PubMedCrossRef
54.
Tauchmanova L, Selleri C, Esposito M, Di Somma C, Orio F Jr, Bifulco G, Palomba S, Lombardi G, Rotoli B, Colao A (2003) Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14:1013–1019PubMedCrossRef
55.
Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C (2007) Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 92:4536–4545PubMedCrossRef
56.
Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R (2001) High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419–2428PubMedCrossRef
57.
Roodman GD (1997) Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557–1563PubMedCrossRef
58.
Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P (2014) Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis 7:33–42PubMedPubMedCentralCrossRef
59.
60.
Chatterjee R, Kottaridis PD (2002) Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies. Bone Marrow Transplant 30:629–635PubMedCrossRef
61.
Socie G, Stone JV, Wingard JR et al (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 341:14–21CrossRef
62.
Tauchmanova L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A (2002) High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 95:1076–1084PubMedCrossRef
63.
Ferrara JL, Levine JE (2006) Graft-versus-host disease in the 21st century: new perspectives on an old problem. Semin Hematol 43:1–2PubMedCrossRef
64.
Schulte CM, Beelen DW (2004) Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 103:3635–3643PubMedCrossRef
65.
Epstein S (1996) Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1–7PubMedCrossRef
66.
Lai CC, Chen WS, Chang DM, Tsao YP, Wu TH, Chou CT, Tsai CY (2015) Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only. Osteoporos Int 26:601–610PubMedCrossRef
67.
Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMedCrossRef
68.
Hui SK, Khalil A, Zhang Y, Coghill K, Le C, Dusenbery K, Froelich J, Yee D, Downs L (2010) Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation. Am J Obstet Gynecol 203(353):e351–e357
69.
Higham CE, Faithfull S (2015) Bone health and pelvic radiotherapy. Clin Oncol (R Coll Radiol) 27:668–678CrossRef
70.
May KP, West SG, McDermott MT, Huffer WE (1994) The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 37:201–206PubMedCrossRef
71.
Rehman MU, Tahir M, Ali F, Qamar W, Lateef A, Khan R, Quaiyoom A, Oday OH, Sultana S (2012) Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem 365:119–127PubMedCrossRef
72.
Le Meignen M, Auquier P, Barlogis V et al (2011) Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 118:1481–1489PubMedCrossRef
73.
McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, Majhail NS (2011) Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 46:1–9CrossRefPubMed
74.
Horwitz ME (2011) Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 23:197–202PubMedCrossRef
75.
Kwee TC, de Klerk JM, Nievelstein RA (2011) Imaging of bone marrow involvement in lymphoma: state of the art and future directions. ScientificWorldJournal 11:391–402PubMedPubMedCentralCrossRef
76.
Daldrup-Link HE, Henning T, Link TM (2007) MR imaging of therapy-induced changes of bone marrow. Eur Radiol 17:743–761PubMedCrossRef
77.
Park JM, Jung HA, Kim DW, Lee JW, Kim CC, Hahn ST (2001) Magnetic resonance imaging of the bone marrow after bone marrow transplantation or immunosuppressive therapy in aplastic anemia. J Korean Med Sci 16:725–730PubMedPubMedCentralCrossRef
78.
Patriarca F, Carobolante F, Zamagni E et al (2015) The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 21:1068–1073PubMedCrossRef
79.
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socie G (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 37:249–261PubMedCrossRef
80.
Majhail NS, Rizzo JD, Lee SJ et al (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:348–371PubMedCrossRef
81.
Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj Fuleihan G, Kecskemethy HH, Jaworski M, Gordon CM, International Society for Clinical Densitometry (2014) Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom 17:225–242
82.
Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRef
83.
Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258PubMedCrossRef
84.
Pundole X, Murphy WA, Ebede CC et al (2018) Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13:38PubMedCrossRef
85.
Clowes JA, Eastell R (2000) The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 14:213–232PubMedCrossRef
86.
Vasikaran SD (2009) Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women? Nat Clin Pract Endocrinol Metab 5:12–13PubMedCrossRef
87.
Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420CrossRefPubMed
88.
Sproat L, Bolwell B, Rybicki L, Dean R, Sobecks R, Pohlman B, Andresen S, Sweetenham J, Copelan E, Kalaycio M (2011) Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 17:1079–1083PubMedCrossRef
89.
Urbain P, Ihorst G, Biesalski HK, Bertz H (2012) Course of serum 25-hydroxyvitamin D(3) status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. Ann Hematol 91:759–766PubMedCrossRef
90.
Glotzbecker B, Ho VT, Aldridge J, Kim HT, Horowitz G, Ritz J, Soiffer R, Avigan D, Rosenblatt J (2013) Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant 48:593–597PubMedCrossRef
91.
Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K, Makela P, Keto P, Ruutu T (1999) A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355–361PubMedCrossRef
92.
Frisk P, Arvidson J, Ljunggren O, Gustafsson J (2012) Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D. Bone Marrow Transplant 47:657–662PubMedCrossRef
93.
94.
95.
Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691PubMedPubMedCentralCrossRef
96.
Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ (2005) Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90:3877–3885PubMedCrossRef
97.
Tauchmanova L, De Simone G, Musella T, Orio F, Ricci P, Nappi C, Lombardi G, Colao A, Rotoli B, Selleri C (2006) Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 37:81–88PubMedCrossRef
98.
Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR (2006) Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 91:3835–3843PubMedCrossRef
99.
Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ (2013) Intermittent zoledronic acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 19:1361–1367PubMedCrossRef
100.
Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D’Souza AB, Ganly P, Ebeling P, Wong E (2017) An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial. Bone Marrow Transplant 52:1288–1293PubMedCrossRef
101.
Chae YS, Kim JG, Moon JH, Kim SN, Lee SJ, Kim YJ, Sohn SK (2009) Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 44:35–41PubMedCrossRef
102.
Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C (2005) Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90:627–634PubMedCrossRef
103.
Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int 18:1439–1450PubMedCrossRef
104.
Body JJ (2005) Bisphosphonates in oncology: focus on clinical experience with pamidronate. Am J Cancer 4:293–305CrossRef
105.
Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347PubMedCrossRef
106.
Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23PubMedCrossRef
107.
de Villiers TJ, Hall JE, Pinkerton JV, Perez SC, Rees M, Yang C, Pierroz DD (2016) Revised global consensus statement on menopausal hormone therapy. Maturitas 91:153–155PubMedCrossRef
108.
Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 21:1657–1680PubMedPubMedCentralCrossRef
109.
Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef
110.
Body JJ (2012) Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther 12:307–322PubMedCrossRef
111.
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980PubMedCrossRef
112.
Pundole X, Partow K, Lu H (2014) Denosumab increases bone mineral density in a young osteoporotic woman on dialysis after allogeneic stem cell transplantation for hematologic malignancy. IBMS BoneKEy:11
113.
Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRef
114.
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRef
115.
116.
Moreau P, San Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52–iv61PubMedCrossRef
117.
Hautmann AH, Elad S, Lawitschka A et al (2011) Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transpl Int 24:867–879PubMedCrossRef
118.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRef
119.
120.
Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433–443CrossRefPubMed
121.
Hadji P, Kyvernitakis I, Kann PH et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967–2978PubMedPubMedCentralCrossRef
122.
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454PubMedCrossRef
123.
Mucowski SJ, Mack WJ, Shoupe D, Kono N, Paulson R, Hodis HN (2014) Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women. Fertil Steril 101:1117–1122PubMedPubMedCentralCrossRef
124.
Castelo-Branco C, Pons F, Martinez de Osaba MJ, Garrido J, Fortuny A (1996) Menstrual history as a determinant of current bone density in young hirsute women. Metabolism 45:515–518PubMedCrossRef
125.
Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641–648PubMedCrossRef
126.
Metadata
Title
Bone management in hematologic stem cell transplant recipients
Authors
D. L. Kendler
J. J. Body
M. L. Brandi
R. Broady
J. Cannata-Andia
M. J. Cannata-Ortiz
A. El Maghraoui
G. Guglielmi
P. Hadji
D. D. Pierroz
T. J. de Villiers
R. Rizzoli
P. R. Ebeling
for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease
Publication date
01-12-2018
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-018-4669-4

Other articles of this Issue 12/2018

Osteoporosis International 12/2018 Go to the issue

Original Article

Incidence and risk factors for hip fracture in elderly patients undergoing lumbar spine surgery: a nationwide database study with 11-year follow-up

Original Article

Menstrual and reproductive factors and risk of vertebral fractures in Japanese women: the Japan Public Health Center-based prospective (JPHC) study

Original Article

Impact of prescription drugs on second fragility fractures among US Medicare patients

Original Article

Tight control: a new therapeutic strategy in the management of osteoporotic patients

Review

Diagnosis and management of bone fragility in diabetes: an emerging challenge

Original Article

Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women